Good morning, everyone, and welcome to another working week. We hope the weekend respite was relaxing and invigorating, because that oh-so predictable routine of online calls and deadlines has returned. But what can you do? After all, the world — such as it is — keeps spinning. So best to reach for a cup of stimulation. Our choice today is maple pecan, a sweet start to the day. By all means, feel free to join us. Meanwhile, we have assembled another roster of items of interest to help you start the day. We hope all goes well on your journey and do keep us in mind if you hear anything juicy. …
The U.S. Food and Drug Administration is reviewing reports suggesting the Moderna (MRNA) Covid-19 vaccine can cause heart problems in some adolescents, The New York Times writes. Moderna requested authorization for use of its vaccine in children ages 12 to 17 years old in June, but the agency has not yet ruled on the application, prompting speculation about reasons for the delay. The FDA review may not be completed until January 2022. The European Medicines Agency approved the vaccine for use in adolescents in July. But since then, several European countries paused the use of the vaccine in people 30 and younger, citing concerns about myocarditis — an inflammation of the heart muscle.
Create a display name to comment
This name will appear with your comment